4361-44-8

Basic information

• Product Name: 3-CYCLOHEXYL-PROPYLAMINE
• Synonyms: 3-CYCLOHEXYL-PROPYLAMINE;CyclohexanepropanaMine
• CAS NO: 4361-44-8
• Molecular Formula: C₉H₁₉N
• Molecular Weight: 141.25
• Mol File: 4361-44-8.mol

Chemical Properties

• Boiling Point: 191.846 °C at 760 mmHg
• Flash Point: 64.68 °C
• Appearance: /
• Density: 0.86 g/cm³
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-CYCLOHEXYL-PROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CYCLOHEXYL-PROPYLAMINE(4361-44-8)
• EPA Substance Registry System: 3-CYCLOHEXYL-PROPYLAMINE(4361-44-8)

Safety Data

• Hazardous Substances Data: 4361-44-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Cyclohexyl-propylamine is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and medications due to its reactive amine group.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Cyclohexyl-propylamine serves as a precursor in the production of herbicides, aiding in the development of effective weed control agents for agricultural applications.
Used in Corrosion Inhibition:
3-Cyclohexyl-propylamine is utilized as a corrosion inhibitor in various industrial processes, helping to protect materials from degradation and extending their service life by preventing chemical or electrochemical reactions that cause corrosion.
Used in Organic Synthesis:
3-Cyclohexyl-propylamine is employed as a versatile building block in the synthesis of a range of other organic compounds, showcasing its utility in the broader field of organic chemistry for creating new molecules with potential applications in various industries.

Upstream product

• 41010-09-7 3-cyclohexylpropionitrile 
• 144290-77-7 N-[3-cyclohexylprop-1-yl]phthalimide 
• 1124-62-5 3-cyclohexylpropyl chloride 
• 1124-63-6 3-cyclohexylpropan-1-ol 
• 34094-21-8 (3-bromopropyl)cyclohexane 
• 80053-69-6 cyclohexanone oxime methanesulfonate 
• 100-64-1 cyclohexanone-oxime 
• 3338-05-4 2-Propyl-1-aza-cyclohept-1-en 
• 701-97-3 cyclohexanepropionic acid 
• 39098-75-4 3-cyclohexylpropionyl chloride 
• 4361-29-9 3-cyclohexylpropanamide 

Downstream Products

• 124499-02-1 (2R,3R,4S,5R)-2-[6-Amino-2-(3-cyclohexyl-propylamino)-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol 
• 76210-61-2 1-(3-Cyclohexyl-propylamino)-3-phenoxy-propan-2-ol; hydrochloride 
• 1027903-93-0 [(S)-5-tert-Butoxycarbonylamino-5-(3-cyclohexyl-propylcarbamoyl)-pentyl]-carbamic acid benzyl ester 
• 1025966-12-4 [(S)-5-((S)-3-Benzyloxy-2-tert-butoxycarbonylamino-propionylamino)-5-(3-cyclohexyl-propylcarbamoyl)-pentyl]-carbamic acid benzyl ester 
• 1026387-78-9 [(S)-5-[(S)-2-(11-Azido-undecanoylamino)-3-benzyloxy-propionylamino]-5-(3-cyclohexyl-propylcarbamoyl)-pentyl]-carbamic acid benzyl ester 
• 144290-65-3 N-Benzoyl-N'-(3-cyclohexyl-propyl)-N''-[3-(1H-imidazol-4-yl)-propyl]-guanidine 
• 144478-16-0 N-(3-Cyclohexyl-propyl)-N'-[3-(1H-imidazol-4-yl)-propyl]-guanidine; hydrochloride 
• 1048974-13-5 C₂₃H₃₀N₄O₂ 
• 1150267-72-3 C₂₉H₂₉F₃N₄O₂ 
• 1192559-67-3 1-cyano-3-(3-cyclohexylpropyl)-2-phenylisourea 
• 1243599-71-4 C₁₅H₂₁N₃O₆S 
• 454646-67-4 3-(1H-imidazol-4-yl)propyl 3-cyclohexylpropylcarbamate hydrogen maleate 
• 93489-29-3 C₁₀H₁₇NO 

Relevant articles and documents

Cyclohexyl-substituted non-fullerene small-molecule acceptors for organic solar cells

In this paper, two cyclohexyl-substituted non-fullerene small molecules, T2-Cy6MRH and T2-Cy6PRH, are designed to have the same molecular backbone of a bithiophene (T2) core and rhodanine (RH) end groups. T2-Cy6MRH and T2-Cy6PRH can be synthesized via two

Remote Regioselective Radical C-H Functionalization of Unactivated C-H Bonds in Amides: The Synthesis of gem-Difluoroalkenes

The site-selective functionalization of unactivated aliphatic amines is an attractive and challenging synthetic approach. We herein report a general strategy for the remote site-selective functionalization of unactivated C(sp3)-H bonds in amides by photogenerated amidyl radicals to form gem-difluoroalkenes with trifluoromethyl-substituted alkenes. The site selectivity is controlled by a 1,5-hydrogen atom transfer (HAT) process of the amide. This photocatalyzed transformation shows both chemo- and site-selectivity, facilitating the formation of a secondary, tertiary, or quaternary carbon center.

Remote Directed Isocyanation of Unactivated C(sp3)-H Bonds: Forging Seven-Membered Cyclic Ureas Enabled by Copper Catalysis

Reported herein is an unprecedented copper-catalyzed site-selective ?-C(sp3)-H bonds activation of aliphatic sulfonamides for constructing the synthetically useful seven-membered N-heterocycles. A key to success is the use of in-situ-formed amide radicals, to activate the inert C(sp3)-H bond, and inexpensive TMSNCO, as a coupling reagent under mild conditions. To the best of our knowledge, this represents the first use of alkylamine derivatives as a five-membered synthon to prepare a seven-membered N-heterocycles.

Copper-Catalyzed Amide Radical-Directed Cyanation of Unactivated Csp3-H Bonds

A method for site-selective intermolecular δ/?-Csp3-H cyanation of aliphatic sulfonamides is developed using TsCN as the cyanating reagent, catalyzed by a Cu(I)/phenanthroline complex. The mild, expeditious, and modular protocol allows efficient remote Csp3-H cyanation with good functional group tolerance and high regioselectivity. Mechanistic studies indicate that the reaction might proceed through a Cu(I)-mediated N-F bond cleavage to generate an amidyl radical, 1,5-HAT, and cyano group transfer of the resulting carbon radical with TsCN.

Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure

A series of flexible urea derivatives have been synthesized and demonstrated as selective cardiac myosin ATPase activator. Among them 1-phenethyl-3-(3-phenylpropyl)urea (1, cardiac myosin ATPase activation at 10?μM?=?51.1%; FS?=?18.90; EF?=?12.15) and 1-benzyl-3-(3-phenylpropyl)urea (9, cardiac myosin ATPase activation?=?53.3%; FS?=?30.04; EF?=?18.27) showed significant activity in?vitro and in?vivo. The change of phenyl ring with tetrahydropyran-4-yl moiety viz., 1-(3-phenylpropyl)-3-((tetrahydro-2H-pyran-4-yl)methyl)urea (14, cardiac myosin ATPase activation?=?81.4%; FS?=?20.50; EF?=?13.10), and morpholine moiety viz., 1-(2-morpholinoethyl)-3-(3-phenylpropyl)urea (21, cardiac myosin ATPase activation?=?44.0%; FS?=?24.79; EF?=?15.65), proved to be efficient to activate the cardiac myosin. The potent compounds 1, 9, 14 and 21 were found to be selective for cardiac myosin over skeletal and smooth myosins. Thus, these urea derivatives are potent scaffold to develop as a newer cardiac myosin activator for the treatment of systolic heart failure.

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

The present invention relates to a compound having a cardiotonic activating function and a pharmaceutical composition containing the same. The composition comprising the compound according to the present invention is effective in preventing or treating heart failure. In addition, the compound is represented by chemical formula 2 or is pharmaceutically acceptable salt thereof.COPYRIGHT KIPO 2016

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

Disclosed are a compound having cardiotonic activity and a pharmaceutical composition containing the same, and the composition containing the compound, according to the present invention, is useful for preventing and treating heart failure.COPYRIGHT KIPO 2016

Novel compounds and compositions for treating diseases asociated with protease activity

Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.

Synthesis and histamine H2 agonistic activity of arpromidine analogues: replacement of the pheniramine-like moiety by non-heterocyclic groups

Analogues of the potent histamine H2 agonist arpromidine, characterized by non-hetrocyclic groups (phenyl, cyclohexyl, alkyl) instead of the pheniramine-like portion, were prepared and tested for their H2 agonistic and H1 antagonistic activity in the isolated guiea pig right atrium and ileum, respectively.In the diphenylpropylguanidine series an increase in H2 agonistic potency resulted from mono- or difluorination at one or both phenyl rings in the meta and/or para position (pD2 7.75 vs pD2 = 7.15 for the unsubstituted parent compound).Compounds chlorinated atboth phenyl rings were considerably less potent.Highest combined H2 agonistic/H1 antagonistic potency was found in the 4-fluorophenyl series.The arpromidine analogue with cyclohexyl and methyl group instead of phenyl and pyridine ring proved to be 30 times more potent than histamine in the atrium.The H1 antagonistic potency in cyclohexyl compounds was lower than in the diaryl series.Thus, aromatic rings appear not to be required for high H2 agonistic potency but are useful for combined H2 agonistic/H1 antagonistic activity. histamine / H2 receptor / H2 agonist / arpromidine / impromidine / H1 antagonist / antihistamine